UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss including noncontrolling interests in subsidiaries	$ (6,570)	$ (92,360)
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash used in operating activities:
Depreciation and amortization	10,152	10,140
Amortization of debt discount and issuance costs	0	90
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives	(3,954)	3,941
Change in fair value of Series A warrants	0	(1,895)
Change in fair value of Series B warrants	(2,762)	(36,636)
Compensation expense for share-based awards	2,324	3,288
(Gain) loss on foreign currency exchange	(25)	4,530
Change in fair value of equity securities	(18,783)	266,202
Gain (loss) on sale of equity securities	9,360	(114,434)
Earnings on equity investment in joint venture	(3,375)	(42,935)
Deferred income taxes	(1,063)	(15,971)
Changes in assets and liabilities:
Accounts receivable	2,982	2,242
Inventories	1,847	(4,872)
Prepaid expenses and other assets	(1,395)	(1,078)
Accounts payable and accrued expenses	(5,623)	4,984
Royalties and contingent legal fees payable	597	795
Deferred revenue	(149)	371
Net cash used in operating activities	(17,962)	(13,598)
Cash flows from investing activities:
Patent acquisition	0	(5,000)
Purchases of equity securities	(8,678)	(107,537)
Sales of equity securities	15,198	236,164
Distributions received from equity investment in joint venture	2,249	1,178
Purchases of property and equipment	(152)	(552)
Net cash provided by investing activities	8,617	124,253
Cash flows from financing activities:
Repurchase of common stock	0	(50,988)
Paydown of Senior Secured Notes	(60,000)	(120,000)
Dividend on Series A Redeemable Convertible Preferred Stock	(1,400)	(2,099)
Taxes paid related to net share settlement of share-based awards	(595)	(1,520)
Proceeds from exercise of stock options	235	0
Net cash provided by (used in) financing activities	66,351	(174,607)
Effect of exchange rates on cash and cash equivalents	(59)	(3,535)
Increase (decrease) in cash and cash equivalents	56,947	(67,487)
Cash and cash equivalents, beginning	287,786	309,361
Cash and cash equivalents, ending	344,733	241,874
Supplemental schedule of cash flow information:
Interest paid	2,380	5,431
Income taxes paid	722	209
Noncash investing and financing activities:
Distribution to noncontrolling interests in subsidiaries	1,126	586
Gain On Warrant Exercises	(1,525)	0
Series B
Cash flows from financing activities:
Proceeds from Warrant Exercises	49,000	0
Rights Offering
Cash flows from financing activities:
Proceeds from Warrant Exercises	$ 79,111	$ 0